Lupin

Who are the top shareholders of the Lupin?

The top shareholders of Lupin include Lupin Investments Pvt Ltd with 45.38%, institutional investors with 38 mutual fund schemes holding 17.55% and 872 foreign institutional investors holding 21.46%, and HDFC Trustee Company Ltd as the highest public shareholder at 3.22%. Individual investors account for 5.1% of the holdings.

The top shareholders of Lupin include the promoters, with Lupin Investments Pvt Ltd holding the largest stake at 45.38%. Additionally, institutional investors play a significant role, with 38 mutual fund schemes collectively holding 17.55% and 872 foreign institutional investors (FIIs) holding 21.46%. The highest public shareholder is HDFC Trustee Company Ltd through the HDFC Balanced Advantage Fund, which holds 3.22%. Individual investors account for 5.1% of the holdings.

how big is Lupin?

As of Jun 06, Lupin Ltd. has a market capitalization of 91,339.09 Cr, with recent net sales of 22,707.90 Cr and a net profit of 3,281.62 Cr over the last four quarters.

Market Cap: Lupin Ltd. has a market capitalization of 91,339.09 Cr and is classified as a Large Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 22,707.90 Cr. The sum of Net Profit for the same period is 3,281.62 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 14,290.29 Cr, while Total Assets amount to 23,694.65 Cr.

What is the bonus history of the Lupin?

Lupin Ltd. announced a 1:1 bonus issue on August 11, 2006, with a record date of August 14, 2006, allowing shareholders to receive an additional share for each share owned.

Lupin Ltd. has a bonus history that includes a notable 1:1 bonus issue announced on August 11, 2006. The record date for this bonus was August 14, 2006. This means that shareholders on record as of that date received an additional share for each share they owned.

Has Lupin declared dividend?

Yes, Lupin Ltd. has declared a 400% dividend, amounting to ₹8 per share, with an ex-date of July 16, 2024. Despite a recent 6.04% decline in the last 6 months, the company has shown strong total returns over longer periods, particularly a 234.26% return over the past 3 years.

Lupin Ltd. has declared a 400% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 400%<BR>- Amount per share: 8<BR>- Ex-date: 16 Jul 24<BR><BR>Dividend Yield: 0.4%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -6.04%, with a dividend return of 0%, resulting in a total return of -6.04%.<BR><BR>Over the past year, the price return was 24.64%, the dividend return was 0.50%, leading to a total return of 25.14%.<BR><BR>In the 2-year period, the price return reached 143.95%, with a dividend return of 1.45%, culminating in a total return of 145.4%.<BR><BR>For the last 3 years, the price return was 231.65%, the dividend return was 2.61%, resulting in a total return of 234.26%.<BR><BR>Over the past 4 years, the price return stood at 62.73%, with a dividend return of 1.93%, leading to a total return of 64.66%.<BR><BR>In the 5-year period, the price return was 122.08%, the dividend return was 3.18%, resulting in a total return of 125.26%.<BR><BR>Overall, Lupin Ltd. has declared a substantial dividend, and the total returns over various periods indicate a generally positive performance, particularly in the longer-term horizons, despite a recent decline in the short term.

Who are the peers of the Lupin?

Lupin's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Aurobindo Pharma, Abbott India, Alkem Lab, Glaxosmi. Pharma, and Glenmark Pharma. In terms of management risk, growth, and capital structure, Lupin is rated average, with a 1-year return of 23.25%, higher than Aurobindo Pharma but lower than Divi's Lab at 51.96%.

Peers: The peers of Lupin are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Aurobindo Pharma, Abbott India, Alkem Lab, Glaxosmi. Pharma, and Glenmark Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Abbott India, and Glaxosmi. Pharma, while Good management risk is found at Divi's Lab., Torrent Pharma, Aurobindo Pharma, Alkem Lab, and Glenmark Pharma. Average management risk is noted for Lupin. In terms of Growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Lupin, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Aurobindo Pharma, Alkem Lab, and Glaxosmi. Pharma. Excellent capital structure is present in Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Aurobindo Pharma, Abbott India, Alkem Lab, and Glaxosmi. Pharma, while Good capital structure is found at Torrent Pharma and Lupin.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while Aurobindo Pharma has the lowest at -6.51%. Lupin's own 1-year return of 23.25% is higher than Aurobindo Pharma's but lower than Divi's Lab.'s. Additionally, the peers with negative six-month returns include Aurobindo Pharma, Alkem Lab, and Lupin.

Who are in the management team of Lupin?

As of March 2023, the management team of Lupin includes M D Gupta (Chairman), Nilesh Deshbandhu Gupta (Managing Director), Vinita Gupta (CEO), R V Satam (Company Secretary), and several independent directors including Jean-Luc Belingard, Mark D McDade, K B S Anand, and Punita Kumar Sinha, along with Ramesh Swaminathan (CFO). They collectively oversee the company's operations and strategic direction.

As of March 2023, the management team of Lupin includes the following individuals:<BR><BR>1. M D Gupta - Chairman (Non-Executive)<BR>2. Nilesh Deshbandhu Gupta - Managing Director<BR>3. Vinita Gupta - Director & Chief Executive Officer<BR>4. R V Satam - Company Secretary & Compliance Officer<BR>5. Jean-Luc Belingard - Independent Director<BR>6. Ramesh Swaminathan - Executive Director & Chief Financial Officer<BR>7. Mark D McDade - Independent Director<BR>8. K B S Anand - Independent Director<BR>9. Punita Kumar Sinha - Independent Director<BR><BR>These members play various roles in guiding and overseeing the company's operations and strategic direction.

What does Lupin do?

Lupin Ltd. is a global pharmaceutical company that develops and markets branded and generic drugs, biotechnology products, and active pharmaceutical ingredients. As of March 2025, it reported net sales of ₹56,671 Cr and a net profit of ₹7,725 Cr, with a market cap of ₹88,831 Cr.

Overview: <BR>Lupin Ltd. is an innovation-led transnational pharmaceutical company producing, developing, and marketing a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>History: <BR>Lupin was incorporated in the year 1968. The latest quarterly results reported are for March 2025, showcasing the company's performance in terms of sales and profits.<BR><BR>Financial Snapshot: <BR>Net Sales: 56,671 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 7,725 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 88,831 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.41% <BR>Debt Equity: 0.07 <BR>Return on Equity: 19.08% <BR>Price to Book: 5.19 <BR><BR>Contact Details: <BR>Address: Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E Mumbai Maharashtra : 400055 <BR>Tel: 91-22-6640 2323 <BR>Email: info@lupin.com <BR>Website: http://www.lupin.com

Is Lupin overvalued or undervalued?

As of November 7, 2025, Lupin is considered fairly valued with a PE ratio of 20.82, an attractive valuation compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -16.17%, supported by strong ROCE and ROE metrics.

As of 7 November 2025, Lupin's valuation grade has moved from very attractive to attractive. The company is currently considered fairly valued. Key ratios include a PE ratio of 20.82, an EV to EBITDA of 13.53, and a PEG ratio of 0.32, indicating strong growth potential relative to its price. <BR><BR>In comparison to its peers, Lupin's valuation appears more favorable; for instance, Sun Pharma has a PE ratio of 35.17 and Divi's Lab stands at 71.11, both categorized as expensive. Other attractive peers include Cipla with a PE of 22.33 and Dr. Reddy's Labs at 17.43. Despite a challenging year-to-date return of -16.17% compared to the Sensex's 6.50%, Lupin's solid ROCE of 22.16% and ROE of 19.08% suggest it remains a robust investment in the pharmaceuticals sector.

How has been the historical performance of Lupin?

Lupin has shown significant growth in net sales and profitability from March 2019 to March 2025, with net sales increasing from 14,664.56 Cr to 22,707.90 Cr and profit after tax rising from 517.27 Cr to 3,306.26 Cr, indicating strong operational efficiency and recovery. Total assets and liabilities also grew, reflecting balanced financial health.

Answer:<BR>The historical performance of Lupin shows a significant upward trend in net sales and profitability over the past few years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Lupin's net sales have steadily increased from 14,664.56 Cr in March 2019 to 22,707.90 Cr in March 2025, reflecting a robust growth trajectory. Total operating income followed a similar pattern, rising from 14,664.56 Cr in March 2019 to 22,707.90 Cr in March 2025. The total expenditure, excluding depreciation, also grew from 12,103.84 Cr in March 2019 to 17,424.59 Cr in March 2025, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) saw a remarkable rise from 2,560.72 Cr in March 2019 to 5,479.13 Cr in March 2025, showcasing improved operational efficiency. Profit before tax surged from 1,405.21 Cr in March 2019 to 4,015.00 Cr in March 2025, while profit after tax increased from 517.27 Cr to 3,306.26 Cr during the same period. The consolidated net profit also reflected this positive trend, climbing from 606.55 Cr in March 2019 to 3,281.62 Cr in March 2025. Additionally, the company's total assets rose from 24,809.54 Cr in March 2020 to 28,645.78 Cr in March 2025, while total liabilities increased from 24,809.54 Cr to 28,645.78 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities improved significantly, reaching 2,999.00 Cr in March 2025, despite a negative cash flow from investing activities of -4,171.00 Cr, which suggests substantial investments in growth initiatives. Overall, Lupin's financial performance demonstrates a strong recovery and growth phase, particularly in the last fiscal year.

Is Lupin technically bullish or bearish?

As of November 28, 2025, Lupin's technical trend has shifted to bullish, supported by strong indicators such as a bullish MACD, Bollinger Bands, and moving averages, along with a recent price action that exceeds the previous close.

As of 28 November 2025, the technical trend for Lupin has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish. Daily moving averages also indicate a bullish trend. The KST shows a bullish signal on the weekly timeframe, while the Dow Theory reflects a mildly bullish stance on both weekly and monthly timeframes. The OBV is mildly bullish on the weekly and bullish on the monthly. Overall, the strength of the bullish trend is reinforced by the recent price action, with today's high surpassing the previous close.

Are Lupin Ltd. latest results good or bad?

Lupin Ltd.'s latest results show strong revenue growth with record net sales of ₹7,167.52 crores, up 24.27% year-on-year, but profitability has declined, with net profit down 20.46% sequentially and operating margins contracting. Investors should be cautious due to these mixed signals regarding sustainability.

Lupin Ltd.'s latest results present a mixed picture. On one hand, the company achieved record net sales of ₹7,167.52 crores in Q3 FY26, reflecting a significant year-on-year growth of 24.27% and a modest quarter-on-quarter increase of 1.70%. This indicates strong revenue momentum, particularly in the US generics and specialty segments.<BR><BR>However, the results also show a concerning decline in profitability. The net profit for the quarter fell by 20.46% sequentially to ₹1,175.55 crores, despite a year-on-year increase of 37.47%. Additionally, the operating profit margin contracted to 31.86% from 34.27% in the previous quarter, and the PAT margin decreased to 16.63% from 21.74%. This margin compression raises questions about the sustainability of profitability, particularly given rising interest costs and potential pricing pressures.<BR><BR>Overall, while the revenue growth is commendable, the decline in profits and margins suggests that investors should approach the results with caution, monitoring future quarters for signs of recovery in profitability.

When is the next results date for Lupin Ltd.?

The next results date for Lupin Ltd. is 07 May 2026.

The next results date for Lupin Ltd. is scheduled for 07 May 2026.

Should I buy, sell or hold Lupin Ltd.?

Why is Lupin Ltd. falling/rising?

As of 30-Apr, Lupin Ltd. is seeing a slight decline in its stock price to Rs 2,303.70, despite strong long-term growth indicators. Short-term performance has lagged behind the Sensex, with reduced investor participation and some recent weakness in momentum, although the company's fundamentals remain strong.

As of 30-Apr, Lupin Ltd. is experiencing a slight decline in its stock price, currently at Rs 2,303.70, which reflects a change of -7.2 (-0.31%). This decrease is occurring despite the company's strong long-term growth indicators, such as a healthy annual growth rate in net sales of 11.42% and an operating profit growth of 33.60%. <BR><BR>In the short term, the stock has underperformed relative to the benchmark Sensex, with a 1-week return of -1.56% compared to the Sensex's -0.97%. Additionally, there has been a notable drop in investor participation, as evidenced by a 14.79% decrease in delivery volume on April 29, which may indicate reduced interest from investors. <BR><BR>While the stock is trading higher than its 50-day, 100-day, and 200-day moving averages, it is lower than its 5-day and 20-day moving averages, suggesting some recent weakness in momentum. Furthermore, the stock is currently 3.17% away from its 52-week high, which could also contribute to the perception of a downward trend.<BR><BR>Despite these short-term challenges, the company maintains a strong financial position with a low debt-to-equity ratio of 0.10 and high institutional holdings at 47.03%. These factors indicate that while the stock may be facing temporary pressures, the underlying fundamentals remain robust, supporting a positive long-term outlook.

Which are the latest news on Lupin?